


RESEARCH

Open Access



A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression

Jialin Ma^{1†}, Zheng Yan^{1†}, Jiuyang Zhang^{1†}, Wenping Zhou¹, Zhihua Yao¹, Haiying Wang¹, Junfeng Chu¹, Shuna Yao¹, Shuang Zhao¹, Peipei Zhang¹, Yuanlin Xu¹, Qingxin Xia², Jie Ma², Bing Wei², Shujun Yang¹, Kangdong Liu³, Yongjun Guo² and Yanyan Liu^{1*} 

Abstract

Background: Early progression after the first-line R-CHOP treatment leads to a very dismal outcome and necessitates alternative treatment for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed to develop a genetic predictive model for early progression and evaluate its potential in advancing alternative treatment.

Methods: Thirty-two hotspot driver genes were examined in 145 DLBCL patients and 5 DLBCL cell lines using next-generation sequencing. The association of clinical features, cell-of-origin, double expression, positive p53 protein, and gene alterations with early progression was analyzed, and the genetic predictive model was developed based on the related independent variables and assessed by the area under receiver operating characteristic. The potential of novel treatment based on the modeling was investigated in in-vitro DLBCL cell lines and in vivo xenograft mouse models.

Results: The frequency of *CD79B* (42.86% vs 9.38%, $p = 0.000$) and *PIM1* mutations (38.78% vs 17.71%, $p = 0.005$) showed a significant increase in patients with early progression. *CD79B* and *PIM1* mutations were associated with complex genetic events, double expression, non-GCB subtype, advance stage and unfavorable prognosis. A powerful genetic predictive model (AUROC = 0.771, 95% CI: 0.689–0.853) incorporating lactate dehydrogenase levels (OR = 2.990, $p = 0.018$), *CD79B* mutations (OR = 5.970, $p = 0.001$), and *PIM1* mutations (OR = 3.021, $p = 0.026$) was created and verified in the other cohort. This modeling for early progression outperformed the prediction accuracy of conventional International Prognostic Index, and new molecular subtypes of MCD and Cluster 5. *CD79B* and *PIM1* mutations indicated a better response to inhibitors of BTK (ibrutinib) and pan-PIM kinase (AZD 1208) through repressing activated oncogenic signaling. Since the two inhibitors failed to decrease BCL2 level, BCL2 inhibitor (venetoclax) was added and demonstrated to enhance their apoptosis-inducing activity in mutant cells with double expression.

Conclusions: The genetic predictive model provides a robust tool to identify early progression and determine precision treatment. These findings warrant the development of optimal alternative treatment in clinical trials.

Keywords: Diffuse large B-cell lymphoma, Early progression, CD79B, PIM1

* Correspondence: yliu@zzu.edu.cn

[†]Jialin Ma, Zheng Yan and Jiuyang Zhang contributed equally to this work.

¹Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dong Ming Road, Zhengzhou 450008, Henan, China

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.